evipedia.ai
← Back

Naringenin for Health & Longevity

Evidence Review created on 11/04/2026 using AI4L / Opus 5.5

Also known as: Naringetol, Salipurol, Naringenine, 4’,5,7-trihydroxyflavanone

Motivation

Naringenin is a natural plant compound from the flavonoid family that gives grapefruit part of its character and is also found in oranges and tomatoes. In the body it acts on the switches that govern how the liver and fat tissue burn or store fat, which is why it has drawn interest as a possible aid to metabolic health as people age.

Naringenin first became widely known through grapefruit, as researchers worked out why the fruit changes how some medicines are handled. Animal studies then examined its effects on body weight and liver fat, and later work explored lifespan in worms and signs of brain aging in mice. It is now sold as a stand-alone supplement at doses far above what food provides.

This review examines what the human evidence shows about naringenin for metabolic health and healthy aging, how strong that evidence is, which safety questions and medicine interactions apply, and what dosing, sourcing and monitoring look like for proactive adults weighing its use.

Benefits - Risks - Protocol - Conclusion

These items give high-level overviews of naringenin’s metabolic, cardiovascular and clinical research.

Three items are listed because other academic reviews are narrower (single diseases such as cancer or brain disorders, or delivery technology) or repeat these overviews. No directly relevant content on naringenin was found from Peter Attia, Andrew Huberman or Chris Kresser (their site searches returned nothing on the compound); Rhonda Patrick mentions naringenin only in passing within a broader microbiome discussion (FoundMyFitness Elinav episode) and in a one-minute summary of a single mouse study (FoundMyFitness Science Digest summary), Life Extension offers only a short 2009 news brief on a single mouse study (Life Extension 2009 newsletter), and Lifespan.io offers only a 2020 news write-up of a single mouse study (Lifespan.io 2020 article), none of them an overview.

Grokipedia

Naringenin

AI-written encyclopedia entry covering naringenin’s chemistry, food sources, biosynthesis and reported pharmacology; useful for quick orientation, though most of its claims rest on preclinical studies.

Examine

Naringenin benefits, dosage, and side effects

Examine’s evidence page (Kamal Patel, updated August 2025) states the evidence is mostly animal and in vitro and links study summaries, including the fatty liver trial, in its research feed.

ConsumerLab

No ConsumerLab article on naringenin exists; the site has not published a review or product test of naringenin supplements.

Systematic Reviews

These systematic reviews and meta-analyses cover naringenin’s human fatty liver data and its main preclinical effect areas.

No systematic review or meta-analysis covers naringenin’s principal risk, its drug transporter and enzyme interactions, so the risk side is unrepresented.

Mechanism of Action

Naringenin is the aglycone (sugar-free form) of naringin, the bitter flavanone (a citrus subclass of flavonoids) of grapefruit (Citrus paradisi); oranges (Citrus sinensis) and tomatoes supply smaller amounts.

  • Liver fat handling: In liver cells and mice, naringenin activates PPAR-α (peroxisome proliferator-activated receptor alpha, a nuclear switch for fat-burning genes) and lowers output of VLDL (very-low-density lipoprotein, the liver’s triglyceride carrier) and apoB (apolipoprotein B, the core protein of particles that build artery plaque) (Mulvihill 2009; Goldwasser 2011).
  • Fat-cell heat production: In human fat-cell cultures it raises UCP1 (uncoupling protein 1, which releases stored energy as heat) and oxygen use (Rebello 2019; Pennington Biomedical group, named inventors on a naringenin–carotenoid patent application, US20210260022A1).
  • Aging pathways: In middle-aged mice it raises SIRT1 (sirtuin 1, an energy-sensing enzyme tied to aging) and brain antioxidant and anti-senescence markers (Piragine 2024).
  • Competing view: Cell effects appear at 1–200 µM (micromolar, a concentration unit), citrus juices give peaks of about 0.6 µM (orange) to 6 µM (grapefruit) (Erlund 2001), and 150–600 mg supplements reach about 16–48 µM for only hours (Rebello 2020).
  • Pharmacology: Half-life about 2.3 hours for pure naringenin (Kanaze 2007) and 2.65–3 hours from orange extract (Rebello 2020); extensive conjugation (tagging with glucuronic acid or sulfate for excretion), with about 6% of a dose recovered in urine (Kanaze 2007). CYP1A2 (a liver drug-metabolizing enzyme) converts it to eriodictyol in vitro (Breinholt 2002). Selectivity is low; human tissue distribution is unknown.

Historical Context & Evolution

Naringin was long known mainly as the compound that makes grapefruit bitter, and naringenin, its aglycone, was studied as a plant pigment and food-chemistry marker rather than as a therapy.

Attention changed in the early 1990s, when grapefruit juice was found to raise blood levels of several medicines and naringenin was proposed as the cause (Fuhr 1993). Controlled tests then showed that naringin solution reproduced little of the felodipine effect (Bailey 1993; Bailey 1998), and furanocoumarins (other grapefruit compounds) such as bergamottin emerged as the main inhibitors of CYP3A4 (the dominant drug-metabolizing enzyme of gut and liver) (Bailey 2000). Naringin nevertheless proved a genuine inhibitor of OATP1A2 (organic anion-transporting polypeptide 1A2, a gut protein that pulls certain drugs into the body) (Bailey 2007).

Between 2008 and 2011, two research lines created therapeutic interest. Huff’s group showed naringenin prevented obesity, fatty liver and reduced insulin response in mice (Mulvihill 2009), and Nahmias’s group showed it blocked hepatitis C virus (HCV) secretion by lowering liver lipoprotein output (Nahmias 2008); a small HCV pilot followed (NCT01091077).

Human data came later: a dose-ranging trial of safety and pharmacokinetics (how the body absorbs and clears a compound) (Rebello 2020) and a 4-week trial in nonalcoholic fatty liver disease (NAFLD, liver fat buildup not caused by alcohol) (Namkhah 2021). Lifespan studies in worms and brain-aging studies in middle-aged mice (Ge 2021; Piragine 2024) moved it into longevity discussions, while the human evidence base remains small.

Expected Benefits

High 🟩 🟩 🟩

Improved Blood Lipids ⚠️ Conflicted

In a randomized controlled trial (RCT) of 44 overweight/obese adults with NAFLD, naringenin 200 mg/day for 4 weeks lowered triglycerides, total cholesterol and LDL-C (low-density lipoprotein cholesterol, the main plaque-building cholesterol) and raised HDL-C (high-density lipoprotein cholesterol, which clears cholesterol from arteries) versus placebo (Tehran group, Namkhah 2021). A Changchun group confirmed this after osteosarcoma (bone cancer) surgery (Zhang 2018). Naringin 500 mg/day left lipids unchanged in one arm of a 194-adult high-cholesterol trial (Demonty 2010). Net reading: direct naringenin trials agree; the null trial used its precursor.

Magnitude: At 4 weeks, triglycerides 92.5 mg/dL lower than placebo (95% CI 51.1–133.9; CI, confidence interval, the plausible range of the true value) (Sairaj 2026) and total cholesterol 32.8 mg/dL lower (95% CI 14.3–51.5) (Wang 2025), network meta-analysis (a meta-analysis comparing many treatments at once) estimates from the single fatty liver trial, in which LDL-C fell and HDL-C rose versus placebo (P = .02 each; P value, the probability of a result this large arising by chance) (Namkhah 2021); at 24 months, LDL-C 3.0 versus 3.9 mmol/L, triglycerides 1.8 versus 2.6 mmol/L and HDL-C 1.6 versus 1.2 mmol/L with naringenin versus placebo (P = .01 each) (Zhang 2018); with naringin, endpoint LDL-C 3.99 versus 4.00 mmol/L with placebo, and no change in total cholesterol, HDL-C or triglycerides (Demonty 2010).

Medium 🟩 🟩

Reduced Liver Fat

The same 4-week RCT reported a lower share of participants at higher ultrasound grades of fatty liver with naringenin 200 mg/day than with placebo (Namkhah 2021). ALT and AST (alanine and aspartate aminotransferase, liver enzymes that rise with liver-cell injury) and the NAFLD fibrosis score (a scarring-risk estimate) did not change. Ultrasound grading is less precise than imaging-based fat measurement, and the trial is unreplicated.

Magnitude: Direction only: the share of participants at higher steatosis (fatty liver) grades fell versus placebo (P < .001), with no between-group change in ALT, AST or fibrosis score (Namkhah 2021); the available literature (the trial abstract and the meta-analysis pooling it, Yang 2022) reports no outcome figure for steatosis grade.

Lower Cancer Recurrence

In a placebo-controlled trial of 95 patients after osteosarcoma surgery, naringenin 20 mg/day was followed by less local recurrence and smaller tumors over about 2 years, with no effect on metastasis (Zhang 2018). A meta-analysis of 32 cell and animal studies found naringenin triggers programmed death of cancer cells (Faramarzi 2022). The trial is single-center, unreplicated and thinly reported, and no trial has tested cancer prevention in healthy adults.

Magnitude: Local recurrence 38.3% with naringenin versus 73.0% with placebo (P < .01) and tumor volume 106.3 versus 225.8 cm³ (P < .05 in the results; the abstract prints “P > 0.01”) after about 2 years; metastasis did not differ (Zhang 2018).

Low 🟩

Lower Body Weight and Visceral Fat ⚠️ Conflicted

In the 4-week NAFLD trial, naringenin reduced BMI (body mass index, weight relative to height) and visceral (abdominal organ) fat versus placebo (Naeini 2022). A network meta-analysis re-estimating this trial found no significant BMI difference (Wang 2025). Net reading: the higher-tier re-analysis outweighs the single-trial signal.

Magnitude: BMI (P = .001) and visceral fat level (P = .039) fell versus placebo, and systolic blood pressure fell marginally (P = .055), with no outcome figure in the trial abstract (Naeini 2022); a network meta-analysis re-estimating the same trial found no significant BMI difference versus placebo (−0.49 kg/m², 95% CI −5.53 to 4.56) (Wang 2025).

Improved Insulin Sensitivity

A woman with diabetes taking 150 mg naringenin three times daily for 8 weeks had lower fasting insulin and a transient rise in metabolic rate (Murugesan 2020). Evidence is a single uncontrolled case report using a whole-orange extract rather than the purified compound.

Magnitude: Fasting insulin 18% lower than baseline after 8 weeks; metabolic rate peaked 3.5% above baseline 1 hour after dosing (single participant, no control group) (Murugesan 2020).

Cardiovascular Protection

Higher dietary flavanone intake was linked to less ischemic stroke (stroke from a blocked artery) in women (Cassidy 2012) and men (Cassidy 2016), and grapefruit juice lowered arterial stiffness in postmenopausal women (Habauzit 2015). All evidence is indirect: food forms mixing naringin with hesperidin and other compounds.

Magnitude: Highest versus lowest flavanone-intake fifth: RR (relative risk, the risk in one group divided by the risk in the other) of ischemic stroke 0.81, 95% CI 0.66–0.99, in women (Cassidy 2012) and HR (hazard ratio, the relative rate of events over time) 0.78, 95% CI 0.62–0.97, in men (Cassidy 2016); pulse wave velocity (arterial stiffness) 7.36 m/s after grapefruit juice versus 7.70 m/s after control drink (Habauzit 2015).

Speculative 🟨

Longer Lifespan and Slower Aging

Naringenin extended lifespan in Caenorhabditis elegans worms (Ge 2021) and reduced brain-aging markers in middle-aged mice (Piragine 2024). No mammalian lifespan or human data exist; the basis is animal work only.

Preserved Muscle Endurance

Dietary naringenin increased running endurance, grip strength and oxygen-using muscle fibers in young and middle-aged mice (Lv 2023). No controlled human muscle studies exist; the basis is mechanistic and animal only.

Brain Health and Mood ⚠️ Conflicted

A rat meta-analysis shows antidepressant-like effects (Huang 2026), but a 36-week trial of a citrus extract with 3 mg naringenin found no cognitive benefit over placebo (Galluzzi 2024). Net reading: no human support yet.

Antiviral Activity

Naringenin blocked hepatitis C virus assembly in liver cells (Goldwasser 2011) and inhibited SARS-CoV-2 (the COVID-19 virus) infection in cell culture (Clementi 2021). The basis is cell work only; the HCV pilot posted no results.

Benefit-Modifying Factors

  • Genetic polymorphisms: CYP1A2 activity varies widely between people and shapes naringenin breakdown (Breinholt 2002); gut bacteria determine how much naringin becomes naringenin (Fuhr 1995). No genotype-stratified benefit data exist.
  • Baseline biomarkers: The lipid and liver-fat effects were seen in people with fatty liver and elevated weight (Namkhah 2021); whether people with normal lipids and no liver fat gain anything is untested.
  • Sex: The stroke association appeared in both women and men (Cassidy 2012; Cassidy 2016); no trial reports sex-specific naringenin effects.
  • Pre-existing conditions: Fatty liver, overweight, diabetes and treated osteosarcoma are the only adult conditions with human naringenin efficacy data (a pediatric pneumonia trial also exists, Yao 2021); benefits in metabolically healthy adults are extrapolated from patients and animals.
  • Age: In men the flavanone–ischemic stroke association was strongest at 65 or older (Cassidy 2016); the osteosarcoma trial enrolled mainly young patients (mean age about 24 years) (Zhang 2018), and no trial targets older adults.
  • Formulation: Whole-orange extract gave about twice the peak serum level of pure naringenin capsules (Rebello 2020), so product form may change effective exposure.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: no adverse outcome of naringenin has been shown in controlled human trials from more than one research group.

Medium 🟥 🟥

No risk reaches Medium: the only placebo-controlled naringenin safety data are a single-dose trial (Rebello 2020) and a 4-week trial (Namkhah 2021) with no excess adverse events, and the interaction evidence comes from naringin or grapefruit juice rather than naringenin.

Low 🟥

Gastrointestinal Discomfort, Headache and Itching ⚠️ Conflicted

Isolated abdominal pain, headache, itching and drowsiness followed single 150–900 mg doses in a placebo-controlled trial (Rebello 2020). Any-event rates were 11–33% per dose versus 22% with placebo, without statistical comparison, and a 4-week trial at 200 mg/day recorded no adverse events (Namkhah 2021). Net reading: short-term tolerability appears placebo-like.

Magnitude: Participants with any adverse event: 3/9 (150 mg), 3/9 (300 mg), 2/9 (600 mg) and 1/9 (900 mg) versus 4/18 with placebo; no serious events (NCT03582553).

Reduced Absorption of Transporter-Dependent Drugs ⚠️ Conflicted

Naringin, which releases naringenin in the gut, lowered fexofenadine absorption via OATP1A2 in a crossover trial (each participant took every treatment) (Bailey 2007), but 1,050 mg naringin capsules left talinolol exposure unchanged (Nguyen 2015). Evidence is indirect: pure naringenin is untested. Net reading: a possible, drug-dependent weakening of affected drugs.

Magnitude: Fexofenadine AUC (area under the curve, total drug exposure) with naringin solution was 75% of that with water (P < .05), and 55% with grapefruit juice (Bailey 2007); talinolol exposure with naringin was 0.90–0.98 times that with talinolol alone, not significant (Nguyen 2015).

Raised Levels of Enzyme-Metabolized Drugs, Including Oral Estradiol ⚠️ Conflicted

Naringenin competitively inhibits CYP3A4 in vitro (Bailey 2000). Grapefruit juice raised estrone after oral estradiol in ovariectomized (ovaries removed) women (Schubert 1994), but naringin solution caused much less felodipine rise than juice (Bailey 1993) and spared caffeine (Ballard 2006). Net reading: unproven, but untested at supplement doses.

Magnitude: Felodipine AUC was 206% of the water value with grapefruit juice, while naringin solution produced “much less” interaction with no figure given; naringin 100–200 mg did not change caffeine pharmacokinetics versus caffeine alone; estrone peak and AUC rose significantly with grapefruit juice versus water, with no figure in the abstract (Bailey 1993; Ballard 2006; Schubert 1994).

Speculative 🟨

Impaired Female Fertility

Naringenin reduced maturation and development of pig egg cells at concentrations reachable with supplements (Solak 2014). The basis is in vitro only; no human reproductive data exist.

Unknown Long-Term Effects

Supplement-dose data end at 4 weeks (trial, Namkhah 2021) and 8 weeks (case report, Murugesan 2020); only 20 mg/day ran 2 years (Zhang 2018). The basis is missing long-term data, not mechanistic or reported harm.

Risk-Modifying Factors

  • Genetic polymorphisms: OATP1A2 activity appears partly inherited (Bailey 2007), and CYP1A2 activity varies widely (Breinholt 2002); either could change interaction size. No genotype-guided safety data exist.
  • Baseline biomarkers: Raised ALT or AST before starting makes later liver readings harder to interpret; the single trial enrolling fatty liver patients reported no worsening (Namkhah 2021).
  • Sex: Women using oral estradiol may see higher estrogen exposure with grapefruit products (Schubert 1994); women trying to conceive face the unresolved egg-cell signal (Solak 2014).
  • Pre-existing conditions: Organ transplant recipients on narrow-margin drugs, people with hormone-sensitive cancers and those with liver disease carry the most interaction or monitoring burden; none has been studied with naringenin.
  • Age: Older adults more often take several interacting drugs (statins, cholesterol-lowering drugs; calcium-channel blockers, blood-pressure drugs; antihistamines, allergy drugs), which raises interaction exposure; no age-specific safety data exist.

Key Interactions & Contraindications

Documented interactions:

  • Fexofenadine and other OATP1A2 substrates (fexofenadine, aliskiren): Naringin cut fexofenadine exposure to 75% of control (Bailey 2007); grapefruit juice lowered aliskiren exposure (Rebello 2012). Consequence: weaker allergy or blood-pressure control. Mitigation: dose separation of at least 4 hours.
  • Felodipine and other CYP3A4 substrates (felodipine, nifedipine): Naringin solution raised felodipine far less than grapefruit juice and was not its main active ingredient (Bailey 1993; Bailey 1998). Consequence: at most a small rise in drug level; mitigation: blood-pressure checks after starting.
  • Nisoldipine (a calcium-channel blocker for blood pressure, CYP3A4 substrate): No interaction found: encapsulated naringin at grapefruit-juice amounts did not change nisoldipine pharmacokinetics in a randomized crossover trial, whereas grapefruit juice doubled exposure (Bailey 1993).
  • Talinolol (a heart-rate and blood-pressure drug, OATP substrate): No interaction found: naringin 1,050 mg/day for 7 days did not change talinolol exposure in a randomized crossover trial (Nguyen 2015).
  • Caffeine (over-the-counter stimulant, CYP1A2 substrate): Grapefruit juice cut caffeine clearance by 23% (Fuhr 1993), but naringin 100–200 mg did not alter caffeine pharmacokinetics (Ballard 2006). Consequence: at most mildly prolonged caffeine effects. Mitigation: lower caffeine intake if jitteriness or poor sleep appears.
  • Theophylline and clozapine (an asthma drug and a schizophrenia drug, CYP1A2 substrates): No interaction found: naringin-rich grapefruit juice did not change theophylline pharmacokinetics in a randomized crossover trial (Fuhr 1995) or steady-state clozapine levels in 15 patients (Lane 2001).
  • Oral estradiol (menopausal hormone therapy): Grapefruit juice raised estrone exposure after oral estradiol (Schubert 1994); naringenin’s share is unknown. Consequence: higher estrogen exposure. Mitigation: prescriber review of breakthrough bleeding or breast tenderness.

Theoretical interactions (inferred from mechanism, not studied in humans):

  • Narrow-margin CYP3A4 drugs (cyclosporine, tacrolimus, simvastatin): Inferred from naringenin’s competitive CYP3A4 inhibition in vitro. Consequence: higher drug levels with kidney or muscle toxicity. Mitigation: drug-level or creatine kinase (muscle-damage marker) checks 1–2 weeks after starting.
  • Other CYP1A2-dependent drugs (tizanidine, ramelteon): Inferred from shared CYP1A2 metabolism. Consequence: raised drug levels with sedation or low blood pressure. Mitigation: blood-pressure and alertness checks after starting.
  • Glucose-lowering drugs and supplements (metformin, insulin, glipizide, berberine): Inferred from additive insulin-sensitizing effects. Consequence: low blood glucose. Mitigation: home glucose checks during the first 2–4 weeks.
  • Lipid-lowering drugs and supplements (atorvastatin, ezetimibe, red yeast rice, bergamot extract): Inferred from additive lipid lowering through liver fat and lipoprotein pathways. Consequence: additive LDL-C reduction. Mitigation: lipid panel 8–12 weeks after starting.
  • Endocrine cancer therapy (tamoxifen, letrozole): Inferred from estrogen-receptor binding and concentration-dependent opposition to tamoxifen in liver cancer cells (Xu 2022). Consequence: possibly reduced treatment effect. Mitigation: oncologist review before use.
  • Other flavonoid supplements and foods (quercetin, hesperidin, grapefruit juice): Inferred from shared transporter, enzyme and conjugation pathways. Consequence: stacked drug-interaction potential. Mitigation: no stacking alongside interacting drugs.
  • QT-prolonging drugs (amiodarone, dofetilide, quinidine): Inferred from hERG (heart potassium channel) blockade, additive with these drugs in vitro (Lin 2008); grapefruit juice lengthened the QT interval (heart-rhythm reset time) by 12.5 ms in volunteers (Zitron 2005). Consequence: arrhythmia (irregular heartbeat) risk. Mitigation: electrocardiogram after starting.

Populations who should avoid Naringenin:

  • Women trying to conceive: Inferred from impaired egg-cell maturation in vitro at supplement-achievable concentrations (Solak 2014); no human data.
  • Pregnancy and breastfeeding: Inferred from naringenin’s hormone-like reproductive effects in vitro at concentrations resembling physiological estrogen levels (Solak 2014); no human safety data in pregnancy or lactation.
  • Transplant recipients and others on narrow-margin CYP3A4 drugs (cyclosporine, tacrolimus): Inferred from in vitro CYP3A4 inhibition; no human data with naringenin.
  • People with hormone-sensitive cancers on endocrine therapy: Inferred from estrogen-receptor activity and in vitro interference with tamoxifen (Xu 2022); no human data.

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • Medication review before starting: Checking all drugs against OATP1A2 and CYP3A4 lists prevents reduced absorption or raised levels of drugs such as fexofenadine, cyclosporine or simvastatin.
  • Dose separation: Taking OATP1A2-dependent drugs (fexofenadine, aliskiren) at least 4 hours apart from naringenin aims to limit the absorption loss seen when naringin was taken together with fexofenadine (Bailey 2007); the interval itself is untested.
  • Low start, stepwise increase: Starting at 100–150 mg/day and rising to 200–600 mg/day over 2–4 weeks allows early detection of gastrointestinal discomfort, headache or itching.
  • Liver enzyme checks: Baseline and 8–12-week ALT and AST screen for long-term effects; ALT above 33 U/L (men) or 25 U/L (women) warrants evaluation per the ACG (American College of Gastroenterology), whose members earn revenue evaluating liver tests (Kwo 2017).
  • Glucose checks with diabetes drugs: Fasting glucose checks during the first 2–4 weeks guard against low blood glucose from additive insulin-sensitizing effects.
  • Avoidance in pregnancy and conception attempts: Stopping naringenin before trying to conceive avoids the unresolved egg-cell maturation signal (Solak 2014).
  • Verified products: Choosing lot-tested products with a certificate of analysis confirms naringenin rather than naringin content, limiting the transporter-dependent drug interaction seen with naringin, which reduced fexofenadine absorption (Bailey 2007).

Therapeutic Protocol

Doses below are cited to their source; other parameters (timing, titration, splitting) reflect common practice.

  • Fatty liver trial regimen: 100 mg twice daily before lunch and dinner for 4 weeks (Namkhah 2021).
  • Long-term low-dose regimen: 20 mg/day for about 2 years after osteosarcoma surgery (Zhang 2018).
  • Metabolic case regimen: 150 mg three times daily from whole-orange extract for 8 weeks (Murugesan 2020).
  • Projected effective dose: 300 mg twice daily, proposed by the Pennington Biomedical group to sustain serum levels active in human fat cells (Rebello 2020).
  • Tested upper range: Single doses up to 900 mg were tolerated (Rebello 2020); 1 g with a cyclodextrin solubilizer was used in the HCV pilot (NCT01091077).
  • Approaches and popularizers: Supplement dosing was developed by Rebello, Greenway and Coulter at Pennington Biomedical (patent-application inventors, US20210260022A1); the food-based alternative, citrus flavanone intake, rests on observational stroke data (Cassidy 2012) and delivers far lower doses.
  • Time of day: Doses before lunch and dinner match the trial; absorption was dose-proportional in both fasted and fed states (Rebello 2020).
  • Half-life: About 2.3–3 hours, with serum levels cleared within 24 hours (Kanaze 2007; Rebello 2020).
  • Single versus split dosing: The short half-life favors two or three divided doses over one daily dose.
  • Genetic polymorphisms: CYP1A2 and OATP1A2 variability may alter exposure (Breinholt 2002; Bailey 2007); no genotype-based dosing exists.
  • Sex differences: No sex-specific dosing data; women on oral estradiol or trying to conceive weigh the estrogen and egg-cell signals.
  • Age: Older adults typically start at the lower end and review interacting drugs; no age-specific dosing data exist.
  • Baseline biomarkers: Elevated triglycerides, LDL-C or liver fat match the trial population (Namkhah 2021); with normal values, response is unknown.
  • Pre-existing conditions: Fatty liver, overweight, diabetes and treated osteosarcoma have human data; liver disease beyond fatty liver and kidney disease have none, favoring lower doses.

Discontinuation & Cycling

  • Duration: Supplement doses have been studied for only 4–8 weeks, and 20 mg/day for about 2 years (Zhang 2018); longer use is common practice when lipid or liver markers respond.
  • Withdrawal effects: None reported; benefits likely fade after stopping, as antiviral effects reversed during washout in liver-cell work (Goldwasser 2011).
  • Tapering: Not needed; with a half-life near 3 hours, naringenin clears within a day.
  • Cycling: No data show tolerance or that cycling preserves effect; cycling is not part of any studied protocol.

Sourcing and Quality

  • Aglycone versus glycoside: Naringenin is absorbed directly, whereas naringin needs gut bacteria to release naringenin, delaying and varying absorption (Fuhr 1995); labels listing naringin or “citrus bioflavonoids” are different products.
  • Purity and identity: A lot-specific certificate of analysis showing at least 98% purity by HPLC (high-performance liquid chromatography, a standard purity test) plus heavy-metal and microbial results indicates a well-controlled product.
  • Extract versus pure compound: Whole sweet-orange extract standardized to 28% naringenin gave about twice the peak serum level of pure naringenin capsules (Rebello 2020).
  • Brands and third-party testing: ConsumerLab has not tested naringenin, and no brand can be singled out on independent data; vendors publishing lot-specific third-party certificates are preferable to those that do not.
  • Advanced formulations: Cyclodextrin, nanoparticle and liposomal forms aim to raise absorption, but only cyclodextrin has a human pilot, with no results posted (NCT01091077).

Practical Considerations

  • Time to effect: Lipid and liver-fat changes were reported after 4 weeks (Namkhah 2021); insulin and weight changes after 8 weeks in a single case (Murugesan 2020).
  • Common pitfalls: Confusing naringin with naringenin; relying on grapefruit juice, which gave naringenin peaks of about 6 µM (Erlund 2001) versus 16–48 µM from supplements (Rebello 2020) and adds furanocoumarin drug interactions; once-daily dosing despite a 3-hour half-life.
  • Regulatory status: Sold in the United States as a dietary supplement; under the Dietary Supplement Health and Education Act, manufacturers, not the FDA (US Food and Drug Administration), evaluate safety and labeling before sale (FDA dietary supplements page).
  • Cost and accessibility: Inexpensive and widely available online; cost is not a barrier.

Interaction with Foundational Habits

  • Sleep: None known: no human study has measured naringenin’s effect on sleep, and the trials reported no insomnia or sedation beyond isolated drowsiness (Rebello 2020). Evening dosing has no known downside.
  • Nutrition: Potentiating in principle: the case-report effects were seen alongside the usual diet (Murugesan 2020), and fed-state absorption was dose-proportional (Rebello 2020). Grapefruit juice adds furanocoumarin drug interactions; citrus fruit adds only small amounts. No nutrient depletion is known.
  • Exercise: Potentiating in animals only: naringenin raised running endurance and oxygen-using muscle fibers in mice via a gene-switch protein, Sp1 (Lv 2023). No human data; no evidence it blunts training adaptations.
  • Stress management: Indirect: a meta-analysis of rat studies found reduced depression-like behavior and lower corticosterone (the rodent stress hormone) (Huang 2026). No human cortisol or stress-response data exist.

Monitoring Protocol & Defining Success

Before starting, baseline testing establishes reference values: a fasting lipid panel, ALT and AST, fasting glucose with fasting insulin, and body weight with waist circumference. People taking narrow-margin drugs such as tacrolimus or cyclosporine also record a baseline drug level.

Ongoing monitoring follows this cadence: lipids, liver enzymes and glucose markers at 8–12 weeks, then every 6–12 months while use continues. Drug levels are rechecked 1–2 weeks after starting when interacting drugs are taken. Success means falling triglycerides and LDL-C, stable or falling liver enzymes, and stable or lower weight and waist; no change after 12 weeks at an adequate dose suggests non-response. People who start with fatty liver can repeat liver imaging, such as ultrasound or elastography (a liver-stiffness scan), after 6–12 months.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
LDL-C <100 mg/dL (“optimal”, NCEP ATP III guideline) Expected to change: fell in the fatty liver trial Fasting lipid panel; NCEP ATP III is the National Cholesterol Education Program Adult Treatment Panel III, a US government panel without member revenue ties (NCEP ATP III 2002); conventional laboratory reference range below 130 mg/dL
Triglycerides <150 mg/dL (“normal”, NCEP ATP III guideline) Expected to change: largest lipid response in the trial 9–12 hour fast; alcohol and recent meals raise values; NCEP ATP III is a US government panel without member revenue ties (NCEP ATP III 2002); conventional reference range below 150 mg/dL
HDL-C ≥60 mg/dL (“high”, NCEP ATP III guideline) Expected to change: rose in the trial Paired with LDL-C in the same panel; NCEP ATP III is a US government panel without member revenue ties (NCEP ATP III 2002); conventional reference range above 40 mg/dL (men) or 50 mg/dL (women)
ALT Below 29–33 U/L (men) or 19–25 U/L (women) (ACG guideline healthy upper limits) Safety check and expected change: rises with liver injury, may fall as liver fat falls ACG is the American College of Gastroenterology; its members evaluate abnormal liver tests, a modest revenue link (Kwo 2017); conventional laboratory upper limits often 40–56 U/L, lab-specific
AST About 10–40 U/L (standard reference range) Safety check: rises with liver or muscle injury Pair with ALT; strenuous exercise in the prior 48 hours can raise AST
Fasting insulin No established target; track change from own baseline Expected to change: fell in the case report Morning fasting sample; calculate HOMA-IR (homeostatic model assessment of insulin resistance) with fasting glucose for trend
Interacting drug level (e.g., tacrolimus trough) No established target; use the drug’s own therapeutic range Safety check: a rise prompts dose change or stopping naringenin Only for people on narrow-margin CYP3A4 drugs; trough (lowest level) sample taken just before the morning dose

Qualitative markers:

  • Gastrointestinal comfort, headache or itching in the first weeks
  • Energy levels and exercise tolerance
  • Body weight and waist circumference trend
  • Continued control of conditions treated with interacting drugs (allergy symptoms, blood pressure)

Emerging Research

  • Fracture recovery trial: NCT06612762 compares 500 mg/day for 14 days, then 250 mg/day to day 90, with placebo in 70 fracture-surgery patients; endpoint inflammatory markers. Registered completion (November 2, 2026) has passed; listed as recruiting, no results posted. Positive: first human anti-inflammatory signal; null: weakens that rationale.
  • Topical fat-reduction pilot: NCT07862920 (SCULPT, 10 participants, not yet recruiting, start January 2027) compares naringenin–β-carotene cream with placebo cream on opposite thighs for 8 weeks; endpoint thigh girth. Positive: supports fat-cell heat production in humans; null: weakens it, without changing oral evidence grades.
  • Combination with β-carotene: Naringenin plus β-carotene converted human white fat cells to a heat-producing phenotype (Coulter 2023); a single-participant study (NCT04697355) completed in 2021 with no results posted.
  • Replication of metabolic findings: The only naringenin fatty liver trial is counted twice in a network meta-analysis (Wang 2025); independent, longer trials with imaging-measured liver fat could confirm or overturn the lipid and liver-fat signals.
  • Aging biology: Worm lifespan and mouse brain and muscle aging data (Piragine 2024; Lv 2023) would gain weight from mammalian lifespan studies, which do not yet exist; failure to extend mammalian lifespan would weaken the longevity rationale.
  • Evidence that weakens the case: A 36-week citrus-extract trial found no cognitive benefit (Galluzzi 2024), and low oral bioavailability (Kanaze 2007) questions whether preclinical concentrations are reached.

Conclusion

Naringenin is the main bitter-tasting plant compound of grapefruit in its sugar-free form, now sold as a stand-alone supplement. Its appeal for health-focused adults rests on a coherent body of animal and cell research showing that it shifts the liver and fat tissue toward burning rather than storing fat, protects against diet-driven weight gain and fatty liver, and touches pathways linked to aging.

The human evidence is far thinner. Two placebo-controlled trials from separate groups reported better blood fats: a short one in people with fatty liver and excess weight, which also found less liver fat, with weight loss less certain, while liver enzyme levels did not change, and a two-year low-dose one after bone cancer surgery, which also reported fewer cancer recurrences. Other human support comes from a single case report and from studies of citrus foods rather than the purified compound. Claims about longer life, muscle preservation, brain health and viral infections rest on worm, rodent and cell studies, and the one long human trial of a low-dose citrus extract found no benefit for thinking skills.

Short-term tolerance appears similar to placebo. The main open questions are interactions with certain medicines, drawn mostly from the related grapefruit compound, a possible effect on estrogen, and the absence of data on supplement doses beyond two months. The research group behind the supplement dosing is named on a related patent application, and the doctors’ society behind the liver-test limits has a modest revenue link. The evidence remains small and uncertain.

Top - Benefits - Risks - Protocol